Clinical trial NCT02470065: Neoadjuvant Afatinib in Early Stage Non Small Cell Lung Cancer.
Official title: Resectable EGFR Mutant NSCLC With (or Without) Afatinib as Neoadjuvant Treatment; REMNANT an Exploratory Study of the EORTC Lung Cancer Group
Study type: INTERVENTIONAL
Overall status: SUSPENDED
Phase: PHASE2
Conditions: Non Small Cell Lung Cancer
Keywords: NSCLC
Early stage
Phase II
Randomized
EGFR mutated
Lead sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Sponsor class: NETWORK
First posted: 2015-06-12
Enrollment: 38
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a multicenter, randomized, 1:1, non-comparative phase II trial. Patients with early stage NSCLC will be randomized between ARM A: neoadjuvant afatinib followed by surgery and ARM B: immediate surgery with curative intent.

Detailed description: This is a multicenter, prospective, open-label, randomized, non-comparative, two-arm phase II trial aiming to evaluate afatinib treatment in pre-operative setting in patients with EGFR mutated NSCLC.

After signing of the informed consent, patients will be registered and screened for eligibility and upon confirmation of all eligibility criteria, patients will be randomized 1:1 to:

* Arm A: once daily afatinib at a dose of 40 mg for 8 weeks followed by surgery with curative intent (anatomical resection and systematic lymph node dissection).
* Arm B: immediate surgery with curative intent (anatomical resection and systematic lymph node dissection).

Response evaluation in the pre-operative arm will be performed through CT scans at baseline, 4 and 8 weeks.

The first 5 patients enrolled in arm A will be part of a safety run-in to check that afatinib treatment doesn't delay surgery.

Eligibility criteria: Inclusion Criteria:

Histological or cytological diagnosis of NSCLC;

* Patients considered operable and with resectable tumor with curative intent (anatomical resection and systematic lymph node dissection) based on evaluation by a thoracic multi-disciplinary team composed of at least a thoracic surgeon, oncologist and radiologist;
* Stage I-III (T1a-3, N0-1, M0 according to UICC version 7) NSCLC by local staging criteria potentially treatable by radical (curative) surgery. Patients with T1 tumor at baseline will be limited to 20%;
* Radiologically measurable disease according to RECIST criteria 1.1; assessed by chest and upper abdomen CT scan within 2 weeks (+1 week) prior to registration); brain CT scan or MRI according to local practice;
* No prior treatment for NSCLC is allowed;
* Adequate tissue in terms of quality and quantity for EGFR local testing.

Exclusion Criteria:

* no adequate bone marrow function within 2 weeks prior to randomization
* no adequate liver function. Patients with Gilbert's syndrome total bilirubin must be below 4 times institutional upper limit of normal; within 2 weeks prior to randomization
* no adequate renal function within 2 weeks prior to randomization
* known positivity to human immunodeficiency virus (HIV), hepatitis B or hepatitis C;
* known history of allergic reactions attributed to compounds of similar chemical or biological composition;
* history of a hematologic or primary solid tumor malignancy, unless no evidence of that disease for 5 years, except pT1-2 prostatic cancer Gleason score \< 6, superficial bladder cancer, non melanoma skin cancer or carcinoma in situ of the cervix;

Primary outcomes:
measure: Decrease in cT-stage
timeFrame: 8 weeks
Secondary outcomes:
measure: Response Rate
timeFrame: 8 weeks
measure: Change in surgical treatment intent and technique
timeFrame: 8 weeks
Other outcomes:
Locations:
Study officials:
affiliation: Royal Marsden NHS Foundation Trust
name: Sanjay Popat, PhD
role: PRINCIPAL_INVESTIGATOR
References: